Stephanie A. Gregory, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
   Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd.
   J Leukoc Biol. 2013
   2013 Jan
   93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7.
   
2. Successful Treatment of Hepatosplenic T-Cell Lymphoma With ESHAP Followed by Autologous Stem Cell Transplant.
   Chalmers AW, Katz DA, Miller IJ, Gregory SA.
   Clin Adv Hematol Oncol. 2013
   2013 Feb
   11(2):109-13. No abstract available.
   
3. Ocular Adnexal MALTomas: Case Series of Patients Treated With Primary Radiation.
   Russell W, Herskovic A, Gessert D, Cohen JA, Rubenstein JB, Gregory SA.
   Clin Adv Hematol Oncol. 2013
   2013 Apr
   11(4):209-14.
   
4. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.
   Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC.
   Exp Hematol. 2012
   2012 Nov
   40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27.
   
5. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
   Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM.
   Blood. 2012
   2012 Jan 19
   119(3):692-5. doi: 10.1182/blood-2011-09-378414. Epub 2011 Nov 23.
   
6. Analysis of very elderly non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
   Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM.
   Br J Haematol. 2012
   2012 Jan
   156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16.
   
7. Relapsed diffuse large B-cell lymphoma--10 years later.
   Jain S, Shah N, Gregory S.
   Clin Adv Hematol Oncol. 2011
   2011 Sep
   9(9):704-8. No abstract available.
   
8. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
   Gregory SA, Mesa RA, Hoffman R, Shammo JM.
   Clin Adv Hematol Oncol. 2011
   2011 Sep
   9(9 Suppl 22):1-16.
   
9. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
   Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.
   Leuk Lymphoma.
   2011 Jun 24
   
10. Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma.
    Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.
    Clin Lymphoma Myeloma Leuk.
    2011 Jun 22
    
11. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.
    Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD.
    Leuk Lymphoma.
    2011 Jul
    52(7):1188-99
    
12. In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice
    Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd
    Exp Hematol
    2011 Feb 1
    
13. Multiple myeloma with multiple extramedullary plasmacytomas.
    Nangia JR, Lakhani AA, Loew JM, Gregory SA.
    Clin Adv Hematol Oncol. 2011
    2011 Aug
    9(8):630-2. No abstract available.
    
14. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ, Gregory SA.
    Semin Hematol.
    2011 Apr
    48 Suppl 1:S24-36
    
15. Intravascular B-cell Lymphoma Following Nodal Diffuse Large B-cell Lymphoma
    Katz DA, Miller IJ, Gregory SA
    Clin Adv Hematol Oncol
    2010 Sep
    8(9):637-42
    
16. The future of CD20 monoclonal antibody therapy in B-cell malignancies
    Czuczman MS, Gregory SA
    Leuk Lymphoma
    2010 Jun
    51(6):983-94
    
17. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM
    J Clin Oncol
    2010 Feb 20
    28(6):1038-46
    
18. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA
    Blood
    2010 Apr 1
    115(13):2578-85
    
19. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
    de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL
    J Clin Oncol
    2009 Oct 20
    27(30):5023-30
    
20. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
    Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E
    Blood
    2009 Apr 16
    113(16):3673-8
    
21. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma
    Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M
    Oncologist
    2009
    14 Suppl 2:4-16
    
22. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary
    Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA
    Oncologist
    2009
    14 Suppl 2:52-4
    
23. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction
    Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA
    Oncologist
    2009
    14 Suppl 2:1-3
    
24. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
    Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA
    Leukemia
    2008 May
    22(5):998-1006
    
25. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma
    Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD
    Clin Adv Hematol Oncol
    2008 Jun
    6(6):437-45
    
26. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture
    Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd
    Transfusion
    2008 Dec
    48(12):2638-44
    
27. Idiopathic hemophagocytic syndrome with a fulminant clinical course
    Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P
    Clin Adv Hematol Oncol
    2008 Aug
    6(8):587-90
    
28. Localized bone disease as a presentation of hairy cell leukemia
    Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S
    Clin Adv Hematol Oncol
    2008 Apr
    6(4):290-4
    

• To watch a brief video of Stephanie A. Gregory, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• We’re gonna cure one cancer at a time. And it’s gonna be one cancer with a new drug, a new, targeted therapy. We’re going away from many intravenous chemotherapy drugs to pills. There’s one leukemia today that was a hundred percent fatal within three years when I was doing my training many years ago. Today that is cured with a pill that patients take. We now have a 95 percent 10-year survival of those patients. So I’ve seen many, many changes over the years, especially in the area that I work in: the lymphomas, the lukemias, the myelomas. Great progress.

  We always say we have the best relationships with our patients because we actually love each other. And the best thing I can ever say to a patient is, “You’re cured.”  And that really makes my day.